These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30984366)

  • 1. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.
    Call JW; Wang Y; Montoya D; Scherzer NJ; Heinrich MC
    Clin Sarcoma Res; 2019; 9():4. PubMed ID: 30984366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.
    Vincenzi B; Nannini M; Badalamenti G; Grignani G; Fumagalli E; Gasperoni S; D'Ambrosio L; Incorvaia L; Stellato M; Spalato Ceruso M; Napolitano A; Valeri S; Santini D; Tonini G; Casali PG; Dei Tos AP; Pantaleo MA
    Ther Adv Med Oncol; 2018; 10():1758835918794623. PubMed ID: 30181783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
    Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 9. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
    Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.
    Van Looy T; Gebreyohannes YK; Wozniak A; Cornillie J; Wellens J; Li H; Vanleeuw U; Floris G; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Sarcoma Res; 2014; 4():10. PubMed ID: 25132955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
    BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
    Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
    Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
    [No Abstract]   [Full Text] [Related]  

  • 14. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland.
    Brzozowska M; Wierzba W; Szafraniec-Buryło S; Czech M; Połowinczak-Przybyłek J; Potemski P; Śliwczyński A
    Med Sci Monit; 2019 May; 25():3846-3853. PubMed ID: 31121600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades.
    Toulmonde M; Dinart D; Brahmi M; Verret B; Jean-Denis M; Ducimetière F; Desolneux G; Méeus P; Palussière J; Buy X; Bouhamama A; Gillon P; Dufresne A; Hénon C; Le Loarer F; Karanian M; Ngo C; Mathoulin-Pélissier S; Bellera C; Le Cesne A; Blay JY; Italiano A
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
    Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study.
    Tan AD; Willemsma K; MacNeill A; DeVries K; Srikanthan A; McGahan C; Hamilton T; Li H; Blanke CD; Simmons CE
    Curr Oncol; 2020 Jun; 27(3):e276-e282. PubMed ID: 32669934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
    Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
    BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.